Eiger Biopharmaceuticals (NASDAQ:EIGR) received a $26.00 target price from equities researchers at Oppenheimer in a research note issued to investors on Thursday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s target price suggests a potential upside of 54.76% from the company’s previous close.
Several other research firms have also recently weighed in on EIGR. ValuEngine raised Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Zacks Investment Research raised Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, March 22nd. Wedbush reaffirmed an “outperform” rating and set a $36.00 price objective on shares of Eiger Biopharmaceuticals in a research report on Thursday, April 26th. Finally, B. Riley initiated coverage on Eiger Biopharmaceuticals in a research report on Wednesday, May 9th. They set a “buy” rating and a $24.00 price target for the company. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $27.63.
Eiger Biopharmaceuticals opened at $16.80 on Thursday, MarketBeat Ratings reports. The company has a quick ratio of 5.85, a current ratio of 4.51 and a debt-to-equity ratio of 0.81. The stock has a market cap of $115.41 million, a PE ratio of -3.46 and a beta of 1.60. Eiger Biopharmaceuticals has a fifty-two week low of $11.35 and a fifty-two week high of $11.90.
In related news, insider Joanne Quan sold 4,000 shares of the stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $10.00, for a total transaction of $40,000.00. Following the completion of the transaction, the insider now directly owns 4,000 shares of the company’s stock, valued at $40,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Prosight Management LP bought a new stake in Eiger Biopharmaceuticals in the fourth quarter valued at approximately $9,469,000. Unterberg Capital LLC bought a new stake in Eiger Biopharmaceuticals in the fourth quarter valued at approximately $698,000. P.A.W. Capital Corp raised its stake in Eiger Biopharmaceuticals by 25.0% in the fourth quarter. P.A.W. Capital Corp now owns 100,000 shares of the biotechnology company’s stock valued at $1,395,000 after buying an additional 20,000 shares during the period. JPMorgan Chase & Co. raised its stake in Eiger Biopharmaceuticals by 295.8% in the third quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 8,748 shares during the period. Finally, Jennison Associates LLC bought a new stake in Eiger Biopharmaceuticals in the fourth quarter valued at approximately $8,430,000. 70.33% of the stock is owned by hedge funds and other institutional investors.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.